Review ArticleReview Article
Open Access

Radiation therapy in head and neck cancer

Afnan F. Alfouzan
Saudi Medical Journal March 2021, 42 (3) 247-254; DOI: https://doi.org/10.15537/smj.2021.42.3.20210660

References

  1. 1.↵
    1. Vigneswaran N,
    2. Williams MD.
    Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 2014; 26: 123–141.
    OpenUrlCrossRef
  2. 2.↵
    1. Chi AC,
    2. Day TA,
    3. Neville BW.
    Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin 2015; 65: 401–421.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Virnig BA,
    2. Warren JL,
    3. Cooper GS,
    4. Klabunde CN,
    5. Schussler N,
    6. Freeman J.
    Studying radiation therapy using SEER-Medicare-linked data. Medical Care 2002; 40: IV–49.
    OpenUrlCrossRef
  4. 4.↵
    1. Barton MB,
    2. Jacob S,
    3. Shafiq J,
    4. Wong K,
    5. Thompson SR,
    6. Hanna TP,
    7. Delaney GP.
    Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol 2014; 112: 140–144.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Saloura V,
    2. Langerman A,
    3. Rudra S,
    4. Chin R,
    5. Cohen EE.
    Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am 2013; 22: 179–215.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. van der Molen L,
    2. van Rossum MA,
    3. Burkhead LM,
    4. Smeele LE,
    5. Hilgers FJ.
    Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review. Eur Arch Otorhinolaryngol 2009; 266: 889–900.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Forastiere AA,
    2. Goepfert H,
    3. Maor M,
    4. Pajak TF,
    5. Weber R,
    6. Morrison W,
    7. Glisson B,
    8. Trotti A,
    9. Ridge JA,
    10. Chao C,
    11. Peters G,
    12. Lee DJ,
    13. Leaf A,
    14. Ensley J,
    15. Cooper J.
    Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–2098.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    1. Wolf GT,
    2. Hong K,
    3. Fisher S.
    The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Marur S,
    2. Forastiere AA.
    Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 2016; 91: 386–396.
    OpenUrlCrossRef
  10. 10.↵
    1. Connell PP,
    2. Hellman S.
    Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009; 69: 383–392.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Lederman M.
    The early history of radiotherapy: 1895-1939. Int J Radiat Oncol Biol Phys 1981; 7: 639–648.
    OpenUrlPubMed
  12. 12.↵
    1. Kaplan HS.
    Historic milestones in radiobiology and radiation therapy. Semin Oncol 1979; 6: 479–489.
    OpenUrlPubMed
  13. 13.↵
    1. Case JT.
    Some early experiences in therapeutic radiology; formation of the American Radium Society. Am J Roentgenol Radium Ther Nucl Med 1953; 70: 487–491.
    OpenUrlPubMed
  14. 14.↵
    1. Coolidge WD.
    Hot-cathode device. [cited 1928]. Available from: https://patents.google.com/patent/US1684263A/en
  15. 15.↵
    1. Mallick I,
    2. Waldron JN.
    Radiation therapy for head and neck cancers. Semin Oncol Nurs 2009; 25: 193–202.
    OpenUrlPubMed
  16. 16.↵
    1. Grégoire V,
    2. Langendijk JA,
    3. Nuyts S.
    Advances in Radiotherapy for Head and Neck Cancer. J Clin Oncol 2015; 33: 3277–3284.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Pfister DG,
    2. Ang KK,
    3. Brizel DM,
    4. Burtness BA,
    5. Cmelak AJ,
    6. Colevas AD, et al.
    Head and neck cancers. J Natl Compr Canc Netw 2011; 9: 596–650.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Duprez F,
    2. Madani I,
    3. Bonte K,
    4. Boterberg T,
    5. Vakaet L,
    6. Derie C, et al.
    Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 2009; 93: 563–569.
    OpenUrlPubMed
  19. 19.↵
    1. Kam MK,
    2. Leung SF,
    3. Zee B,
    4. Chau RM,
    5. Suen JJ,
    6. Mo F, et al.
    Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873–4879.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Lee N,
    2. Harris J,
    3. Garden AS,
    4. Straube W,
    5. Glisson B,
    6. Xia P, et al.
    Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27: 3684–3690.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    1. Lee NY,
    2. de Arruda FF,
    3. Puri DR,
    4. Wolden SL,
    5. Narayana A,
    6. Mechalakos J, et al.
    A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 966–974.
    OpenUrlPubMedWeb of Science
  22. 22.
    1. Fregnani ER,
    2. Parahyba CJ,
    3. Morais-Faria K,
    4. Fonseca FP,
    5. Ramos PA,
    6. de Moraes FY, et al.
    IMRT delivers lower radiation doses to dental structures than 3DRT in head and neck cancer patients. Radiat Oncol 2016; 11: 116.
    OpenUrl
  23. 23.
    1. Lee N,
    2. Xia P,
    3. Quivey JM,
    4. Sultanem K,
    5. Poon I,
    6. Akazawa C, et al.
    Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12–22.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    1. Kam MK,
    2. Teo PM,
    3. Chau RM,
    4. Cheung KY,
    5. Choi PH,
    6. Kwan WH, et al.
    Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004; 60: 1440–1450.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Gupta T,
    2. Agarwal J,
    3. Jain S,
    4. Phurailatpam R,
    5. Kannan S,
    6. Ghosh-Laskar S, et al.
    Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 2012; 104: 343–348.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Lee NY,
    2. Le QT.
    New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol 2008; 35: 236–250.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Kwong DL,
    2. Pow EH,
    3. Sham JS,
    4. McMillan AS,
    5. Leung LH,
    6. Leung WK, et al.
    Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 2004; 101: 1584–1593.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. de Arruda FF,
    2. Puri DR,
    3. Zhung J,
    4. Narayana A,
    5. Wolden S,
    6. Hunt M, et al.
    Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006; 64: 363–373.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Lambrecht M,
    2. Nevens D,
    3. Nuyts S.
    Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer. Strahlenther Onkol 2013; 189: 223–229.
    OpenUrl
  30. 30.↵
    1. Rathod S,
    2. Gupta T,
    3. Ghosh-Laskar S,
    4. Murthy V,
    5. Budrukkar A,
    6. Agarwal J.
    Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol 2013; 49: 634–642.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Otto K.
    Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008; 35: 310–317.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Vanetti E,
    2. Clivio A,
    3. Nicolini G,
    4. Fogliata A,
    5. Ghosh-Laskar S,
    6. Agarwal JP, et al.
    Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT. Radiother Oncol 2009; 92: 111–117.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Fu KK,
    2. Pajak TF,
    3. Trotti A,
    4. Jones CU,
    5. Spencer SA,
    6. Phillips TL, et al.
    A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7–16.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Pignon JP,
    2. Bourhis J,
    3. Domenge CO,
    4. Designé LL
    , Mach-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. The Lancet 2000; 355: 949–955.
    OpenUrl
  35. 35.↵
    1. Forastiere A,
    2. Koch W,
    3. Trotti A,
    4. Sidransky D.
    Head and neck cancer. N Engl J Med 2001; 345: 1890–1900.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.
    1. Overgaard J,
    2. Hansen HS,
    3. Specht L,
    4. Overgaard M,
    5. Grau C,
    6. Andersen E, et al.
    Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. The Lancet 2003; 362: 933–940.
    OpenUrl
  37. 37.↵
    1. Nguyen LN,
    2. Ang KK.
    Radiotherapy for cancer of the head and neck: altered fractionation regimens. The Lancet Oncology 2002; 3: 693–701.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Bourhis J,
    2. Overgaard J,
    3. Audry H,
    4. Ang KK,
    5. Saunders M,
    6. Bernier J, et al.
    Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. The Lancet 2006; 368: 843–854.
    OpenUrl
  39. 39.↵
    1. Park HJ,
    2. Griffin RJ,
    3. Hui S,
    4. Levitt SH,
    5. Song CW.
    Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012; 177: 311–327.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Parvathaneni U,
    2. Laramore GE,
    3. Liao JJ.
    Technical advances and pitfalls in head and neck radiotherapy. J Oncol 2012; 2012: 597467.
    OpenUrlPubMed
  41. 41.↵
    1. Castadot P,
    2. Geets X,
    3. Lee JA,
    4. Christian N,
    5. Grégoire V.
    Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother Oncol 2010; 95: 209–217.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Geets X,
    2. Tomsej M,
    3. Lee JA,
    4. Duprez T,
    5. Coche E,
    6. Cosnard G, et al.
    Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007; 85: 105–115.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Barker Jr JL,
    2. Garden AS,
    3. Ang KK,
    4. O’Daniel JC,
    5. Wang H,
    6. Court LE, et al.
    Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 2004; 59: 960–970.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Mendenhall WM,
    2. Amdur RJ,
    3. Palta JR.
    Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24: 2618–2623.
    OpenUrlAbstract/FREE Full Text
  45. 45.
    1. Schwartz DL,
    2. Garden AS,
    3. Thomas J,
    4. Chen Y,
    5. Zhang Y,
    6. Lewin J,
    7. Chambers MS,
    8. Dong L.
    Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys 2012; 83: 986–993.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Yang H,
    2. Hu W,
    3. Wang W,
    4. Chen P,
    5. Ding W,
    6. Luo W.
    Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2013; 85: e47–e54.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Holliday EB,
    2. Frank SJ.
    Proton radiation therapy for head and neck cancer: a review of the clinical experience to date. Int J Radiat Oncol Biol Phys 2014; 89: 292–302.
    OpenUrlCrossRefPubMed
  48. 48.
    1. Suit H,
    2. Urie M.
    Proton beams in radiation therapy. J Natl Cancer Inst 1992; 84: 155–164.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Mendenhall NP,
    2. Malyapa RS,
    3. Su Z,
    4. Yeung D,
    5. Mendenhall WM,
    6. Li Z.
    Proton therapy for head and neck cancer: rationale, potential indications, practical considerations, and current clinical evidence. Acta Oncol 2011; 50: 763–771.
    OpenUrlPubMed
  50. 50.↵
    1. Lester SY,
    2. Yang WY.
    Principles and management of head and neck cancer. Head and Neck 2012; 30: 617–623.
    OpenUrl
  51. 51.↵
    1. Pignon JP,
    2. le Maître A,
    3. Bourhis J
    ; MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69 (2 Suppl): S112–S114.
    OpenUrlPubMedWeb of Science
  52. 52.↵
    1. Bonner JA,
    2. Harari PM,
    3. Giralt J,
    4. Cohen RB,
    5. Jones CU,
    6. Sur RK, et al.
    Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21–28.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Sroussi HY,
    2. Epstein JB,
    3. Bensadoun RJ,
    4. Saunders DP,
    5. Lalla RV,
    6. Migliorati CA, et al.
    Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 2017; 6: 2918–2931.
    OpenUrl
  54. 54.↵
    1. Vissink A,
    2. Jansma J,
    3. Spijkervet FK,
    4. Burlage FR,
    5. Coppes RP.
    Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14: 199–212.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Cox JD,
    2. Stetz J,
    3. Pajak TF.
    Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–1346.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Cooper JS,
    2. Pajak TF,
    3. Forastiere AA,
    4. Jacobs J,
    5. Campbell BH,
    6. Saxman SB, et al.
    Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937–1944.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Trotti A,
    2. Bellm LA,
    3. Epstein JB,
    4. Frame D,
    5. Fuchs HJ,
    6. Gwede CK, et al.
    Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003; 66: 253–262.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Rosenthal DI,
    2. Lewin JS,
    3. Eisbruch A.
    Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636–2643.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Duncan GG,
    2. Epstein JB,
    3. Tu D,
    4. Sayed SE,
    5. Bezjak A,
    6. Ottaway J, et al.
    Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 2005; 27: 421–428.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Lalla RV,
    2. Saunders DP,
    3. Peterson DE.
    Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am 2014; 58: 341–349.
    OpenUrl
  61. 61.↵
    1. Elting LS,
    2. Cooksley CD,
    3. Chambers MS,
    4. Garden AS
    . Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007; 68: 1110–1120.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Mekhail TM,
    2. Adelstein DJ,
    3. Rybicki LA,
    4. Larto MA,
    5. Saxton JP,
    6. Lavertu P.
    Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 2001; 91: 1785–1790.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Denham JW,
    2. Peters LJ,
    3. Johansen J,
    4. Poulsen M,
    5. Lamb DS,
    6. Hindley A, et al.
    Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 1999; 52: 157–164.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. MacLellan J,
    2. Ali S,
    3. Curtis S,
    4. Baserman J,
    5. Dixon A.
    Analgesia for acute gingivostomatitis: a national survey of pediatric emergency physicians. CJEM 2017; 19: 32–38.
    OpenUrl
  65. 65.↵
    1. Trotti A.
    Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000; 47: 1–12.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Sciubba JJ,
    2. Goldenberg D.
    Oral complications of radiotherapy. Lancet Oncol 2006; 7: 175–183.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    1. Beech N,
    2. Robinson S,
    3. Porceddu S,
    4. Batstone M.
    Dental management of patients irradiated for head and neck cancer. Aust Dent J 2014; 59: 20–28.
    OpenUrl
  68. 68.↵
    1. Porter SR,
    2. Fedele S,
    3. Habbab KM.
    Xerostomia in head and neck malignancy. Oral Oncol 2010; 46: 460–463.
    OpenUrlPubMed
  69. 69.↵
    1. Seikaly H,
    2. Jha N,
    3. McGaw T,
    4. Coulter L,
    5. Liu R,
    6. Oldring D.
    Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 2001; 111: 347–352.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    1. Jha N,
    2. Seikaly H,
    3. McGaw T,
    4. Coulter L.
    Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 2000; 46: 7–11.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Sas R,
    2. Dawes C.
    The intra-oral distribution of unstimulated and chewing-gum-stimulated parotid saliva. Arch Oral Biol 1997; 42: 469–474.
    OpenUrlPubMed
  72. 72.↵
    1. Sood AJ,
    2. Fox NF,
    3. O’Connell BP,
    4. Lovelace TL,
    5. Nguyen SA,
    6. Sharma AK,
    7. Hornig JD,
    8. Day TA.
    Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. Oral Oncol 2014; 50: 77–83.
    OpenUrl
  73. 73.↵
    1. Kufta K,
    2. Forman M,
    3. Swisher-McClure S,
    4. Sollecito TP,
    5. Panchal N.
    Pre-Radiation dental considerations and management for head and neck cancer patients. Oral Oncol 2018; 76: 42–51.
    OpenUrl
  74. 74.↵
    1. Murdoch-Kinch CA,
    2. Zwetchkenbaum S.
    Dental management of the head and neck cancer patient treated with radiation therapy. J Mich Dent Assoc 2011; 93: 28–37.
    OpenUrlPubMed
  75. 75.↵
    1. Kielbassa AM,
    2. Hinkelbein W,
    3. Hellwig E,
    4. Meyer-Lückel H.
    Radiation-related damage to dentition. Lancet Oncol 2006; 7: 326–335.
    OpenUrlCrossRefPubMed
  76. 76.
    1. Gorsky M,
    2. Epstein JB,
    3. Parry J,
    4. Epstein MS,
    5. Le ND,
    6. Silverman S Jr..
    The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97: 190–195.
    OpenUrlPubMedWeb of Science
  77. 77.
    1. Momm F,
    2. Volegova-Neher NJ,
    3. Schulte-Mönting J,
    4. Guttenberger R.
    Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlenther Onkol 2005; 181: 231–236.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Nieuw Amerongen AV,
    2. Veerman EC.
    Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 2003; 11: 226–231.
    OpenUrlPubMed
  79. 79.↵
    1. Jeremic G,
    2. Venkatesan V,
    3. Hallock A,
    4. Scott D,
    5. Hammond A,
    6. Read N,
    7. Franklin J,
    8. Yoo J,
    9. Fung K.
    Trismus following treatment of head and neck cancer. J Otolaryngol Head Neck Surg 2011; 40: 323–329.
    OpenUrl
  80. 80.↵
    1. Goldstein M,
    2. Maxymiw WG,
    3. Cummings BJ,
    4. Wood RE.
    The effects of antitumor irradiation on mandibular opening and mobility: a prospective study of 58 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88: 365–373.
    OpenUrlCrossRefPubMed
  81. 81.↵
    1. Dijkstra PU,
    2. Huisman PM,
    3. Roodenburg JL.
    Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 2006; 35: 337–342.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    1. Bensadoun RJ,
    2. Riesenbeck D,
    3. Lockhart PB,
    4. Elting LS,
    5. Spijkervet FK,
    6. Brennan MT, et al.
    A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer 2010; 18: 1033–1038.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    1. Ichimura K,
    2. Tanaka T.
    Trismus in patients with malignant tumours in the head and neck. J Laryngol Otol 1993; 107: 1017–10120.
    OpenUrlPubMed
  84. 84.↵
    1. Lee IJ,
    2. Koom WS,
    3. Lee CG,
    4. Kim YB,
    5. Yoo SW,
    6. Keum KC,
    7. Kim GE,
    8. Choi EC,
    9. Cha IH.
    Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2009; 75: 1084–1091.
    OpenUrlCrossRefPubMed
  85. 85.
    1. O’Dell K,
    2. Sinha U
    . Osteoradionecrosis. Oral Maxillofac Surg Clin North Am 2011; 23: 455–464.
    OpenUrlPubMed
  86. 86.↵
    1. Ceponis P,
    2. Keilman C,
    3. Guerry C,
    4. Freiberger JJ.
    Hyperbaric oxygen therapy and osteonecrosis. Oral Dis 2017; 23: 141–151.
    OpenUrl
  87. 87.↵
    1. Ben-David MA,
    2. Diamante M,
    3. Radawski JD,
    4. Vineberg KA,
    5. Stroup C,
    6. Murdoch-Kinch CA, et al.
    Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 2007; 68: 396–402.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Gomez DR,
    2. Estilo CL,
    3. Wolden SL,
    4. Zelefsky MJ,
    5. Kraus DH,
    6. Wong RJ,
    7. Shaha AR,
    8. Shah JP,
    9. Mechalakos JG,
    10. Lee NY.
    Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 81: e207–e213.
    OpenUrlPubMed
  89. 89.↵
    1. Jacobson AS,
    2. Buchbinder D,
    3. Hu K,
    4. Urken ML.
    Paradigm shifts in the management of osteoradionecrosis of the mandible. Oral Oncol 2010; 46: 795–801.
    OpenUrlCrossRefPubMedWeb of Science
  90. 90.↵
    1. Bras J,
    2. de Jonge HK,
    3. van Merkesteyn JP.
    Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 1990; 11: 244–250.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.↵
    1. Tahir AR,
    2. Westhuyzen J,
    3. Dass J,
    4. Collins MK,
    5. Webb R,
    6. Hewitt S,
    7. Fon P,
    8. McKay M.
    Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia’s largest study. Asia Pac J Clin Oncol 2015; 11: 68–77.
    OpenUrl
  92. 92.↵
    1. Marx RE.
    Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41: 283–288.
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.↵
    1. Hampson NB,
    2. Holm JR,
    3. Wreford-Brown CE,
    4. Feldmeier J.
    Prospective assessment of outcomes in 411 patients treated with hyperbaric oxygen for chronic radiation tissue injury. Cancer 2012; 118: 3860–3868.
    OpenUrl
  94. 94.↵
    1. Mansfield MJ,
    2. Sanders DW,
    3. Heimbach RD,
    4. Marx RE.
    Hyperbaric oxygen as an adjunct in the treatment of osteoradionecrosis of the mandible. J Oral Surg 1981; 39: 585–589.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords